Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Christopher Haqq currently holds 28,200 shares of Elicio Therapeutics, Inc. (ELTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Christopher Haqq has been a net seller of ELTX stock. They have purchased $0 and sold $7.4M worth of shares.
Christopher Haqq's most recent insider trade was on Sep 30, 2024, when they sold 28,200 shares at $0.00 per share.
Christopher Haqq serves as Executive at Elicio Therapeutics, Inc. (ELTX). They have executed 74 insider transactions totaling $7.4M over their tenure at the company.
Christopher Haqq holds the position of Executive at Elicio Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 11 years and currently hold a stake valued at $0.
Christopher Haqq has shown a selling trading pattern, with $0 in total purchases and $7.4M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Christopher Haqq was on Mar 26, 2018, when they sold $684.9K worth of ATRA shares. This transaction involved 17,227 shares at $39.76 per share.
Christopher Haqq currently owns 28,200 shares of Elicio Therapeutics, Inc. (ELTX), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Christopher Haqq's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Christopher Haqq has 74 Form 4 filings on record as an insider at Elicio Therapeutics, Inc..
Set alerts for Christopher Haqq and 40,000+ other insiders.